These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 22961074)

  • 1. Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and ¹⁸F-fluorodeoxyglucose positron emission tomography.
    Yamashita K; Yoshiura T; Hiwatashi A; Togao O; Yoshimoto K; Suzuki SO; Abe K; Kikuchi K; Maruoka Y; Mizoguchi M; Iwaki T; Honda H
    Neuroradiology; 2013 Feb; 55(2):135-43. PubMed ID: 22961074
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
    Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic utility of intravoxel incoherent motion mr imaging in differentiating primary central nervous system lymphoma from glioblastoma multiforme.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Kitamura Y; Mizoguchi M; Yoshimoto K; Kuga D; Suzuki SO; Baba S; Isoda T; Iwaki T; Iihara K; Honda H
    J Magn Reson Imaging; 2016 Nov; 44(5):1256-1261. PubMed ID: 27093558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiating between Primary Central Nervous System Lymphoma and Glioblastoma: The Diagnostic Value of Combining
    Hatakeyama J; Ono T; Takahashi M; Oda M; Shimizu H
    Neurol Med Chir (Tokyo); 2021 Jun; 61(6):367-375. PubMed ID: 33967177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography.
    Nakajima S; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Arakawa Y; Takagi Y; Miyamoto S; Togashi K
    Clin Imaging; 2015; 39(3):390-5. PubMed ID: 25547624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiating Primary Central Nervous System Lymphomas From Glioblastomas and Inflammatory Demyelinating Pseudotumor Using Relative Minimum Apparent Diffusion Coefficients.
    Wen JB; Huang WY; Xu WX; Wu G; Geng DY; Yin B
    J Comput Assist Tomogr; 2017; 41(6):904-909. PubMed ID: 28708728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating primary central nervous system lymphoma from glioblastoma by time-dependent diffusion using oscillating gradient.
    Kamimura K; Nakano T; Hasegawa T; Nakajo M; Yamada C; Kamimura Y; Akune K; Ejima F; Ayukawa T; Nagano H; Takumi K; Nakajo M; Higa N; Yonezawa H; Hanaya R; Kirishima M; Tanimoto A; Iwanaga T; Imai H; Feiweier T; Yoshiura T
    Cancer Imaging; 2023 Nov; 23(1):114. PubMed ID: 38037172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical primary central nervous system lymphoma and glioblastoma: multiparametric differentiation based on non-enhancing volume, apparent diffusion coefficient, and arterial spin labeling.
    Yu X; Hong W; Ye M; Lai M; Shi C; Li L; Ye K; Xu J; Ai R; Shan C; Cai L; Luo L
    Eur Radiol; 2023 Aug; 33(8):5357-5367. PubMed ID: 37171492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation between primary CNS lymphoma and glioblastoma: qualitative and quantitative analysis using arterial spin labeling MR imaging.
    You SH; Yun TJ; Choi HJ; Yoo RE; Kang KM; Choi SH; Kim JH; Sohn CH
    Eur Radiol; 2018 Sep; 28(9):3801-3810. PubMed ID: 29619520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of
    Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
    J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone-Searching for a practical approach.
    Neska-Matuszewska M; Bladowska J; Sąsiadek M; Zimny A
    PLoS One; 2018; 13(1):e0191341. PubMed ID: 29342201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of diffusion-weighted MRI and [
    Morakote W; Baratto L; Ramasamy SK; Adams LC; Liang T; Sarrami AH; Daldrup-Link HE
    Eur Radiol; 2024 Jan; 34(1):643-653. PubMed ID: 37542653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor.
    Lu S; Gao Q; Yu J; Li Y; Cao P; Shi H; Hong X
    Eur J Radiol; 2016 Oct; 85(10):1722-1727. PubMed ID: 27666608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
    Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
    Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging.
    Kickingereder P; Wiestler B; Sahm F; Heiland S; Roethke M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Radiology; 2014 Sep; 272(3):843-50. PubMed ID: 24814181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
    Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
    Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/MR imaging of lymphoma nodal target lesions: Comparison of PET standardized uptake value (SUV) with MR apparent diffusion coefficient (ADC).
    Bernstine H; Domachevsky L; Nidam M; Goldberg N; Abadi-Korek I; Shpilberg O; Groshar D
    Medicine (Baltimore); 2018 Apr; 97(16):e0490. PubMed ID: 29668631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.